These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18697235)

  • 21. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction.
    Davidson MH; Ballantyne CM
    Am J Cardiol; 2008 Apr; 101(8A):1B-2B. PubMed ID: 18375235
    [No Abstract]   [Full Text] [Related]  

  • 23. Elevated lipoprotein (a) blood levels as the single treatable atherosclerotic risk factor in patients with coronary artery disease.
    Bays H; Dujovne CA; Mays JB
    J Ky Med Assoc; 1993 Nov; 91(11):498-500. PubMed ID: 8270845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Niacin--an additive therapeutic approach for optimizing lipid profile].
    Wieneke H; Schmermund A; Erbel R
    Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ARBITER-2 : evidence that targeting HDL cholesterol slows atherosclerosis.
    Cardiovasc J S Afr; 2005; 16(1):61. PubMed ID: 15778778
    [No Abstract]   [Full Text] [Related]  

  • 26. Niacin therapy lives for another day-maybe?
    Lavie CJ; Dinicolantonio JJ; Milani RV; O'Keefe JH
    J Am Coll Cardiol; 2013 May; 61(21):2197-8. PubMed ID: 23541967
    [No Abstract]   [Full Text] [Related]  

  • 27. Recent trials of lipid lowering.
    Ray KK; Cannon CP; Braunwald E
    Int J Clin Pract; 2007 Jul; 61(7):1145-59. PubMed ID: 17577297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coronary artery disease--more disease, more patients, better treatment.
    Kendall MJ; Nuttall SL
    J Clin Pharm Ther; 2003 Feb; 28(1):1-4. PubMed ID: 12605612
    [No Abstract]   [Full Text] [Related]  

  • 29. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
    Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated lipoprotein(a) and premature coronary heart disease.
    Parsons WB
    JAMA; 1997 Jan; 277(3):209; author reply 210. PubMed ID: 9005264
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapy and clinical trials.
    Elmallah W; Krasuski RA
    Curr Opin Lipidol; 2011 Dec; 22(6):512-3. PubMed ID: 22101564
    [No Abstract]   [Full Text] [Related]  

  • 32. Lipoprotein (a): perspectives from a lipid-referral program.
    Rubenfire M; Vodnala D; Krishnan SM; Bard RL; Jackson EA; Giacherio D; Brook RD
    J Clin Lipidol; 2012; 6(1):66-73. PubMed ID: 22264576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-density lipoprotein particles, coronary heart disease, and niacin.
    Asztalos BF
    J Clin Lipidol; 2010; 4(5):405-10. PubMed ID: 21122684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
    Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
    J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality.
    Khera AV; Patel PJ; Reilly MP; Rader DJ
    J Am Coll Cardiol; 2013 Nov; 62(20):1909-10. PubMed ID: 23933538
    [No Abstract]   [Full Text] [Related]  

  • 36. Is niacin ineffective? Or did AIM-HIGH miss its target?
    Nicholls SJ
    Cleve Clin J Med; 2012 Jan; 79(1):38-43. PubMed ID: 22219232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niacin as antidyslipidemic drug.
    Julius U
    Can J Physiol Pharmacol; 2015 Dec; 93(12):1043-54. PubMed ID: 26370906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.